Skip to main content

Articles

Page 3 of 23

  1. Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomize...

    Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings

    Citation: Alzheimer's Research & Therapy 2021 13:80

    Content type: Research

    Published on:

  2. CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profil...

    Authors: James D. Doecke, Cindy Francois, Christopher J. Fowler, Erik Stoops, Pierrick Bourgeat, Stephanie R. Rainey-Smith, Qiao-Xin Li, Colin L. Masters, Ralph N. Martins, Victor L. Villemagne, Steven J. Collins and Hugo Marcel Vanderstichele

    Citation: Alzheimer's Research & Therapy 2021 13:79

    Content type: Research

    Published on:

  3. Pain is common among individuals with Alzheimer’s disease and related dementias (ADRD), and use of opioids has been increasing over the last decade. Yet, it is unclear to what extent opioids are appropriately ...

    Authors: Yu-Jung Jenny Wei, Siegfried Schmidt, Cheng Chen, Roger B. Fillingim, M. Carrington Reid, Steven DeKosky, Laurence Solberg, Marco Pahor, Babette Brumback and Almut G. Winterstein

    Citation: Alzheimer's Research & Therapy 2021 13:78

    Content type: Research

    Published on:

  4. There is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19).

    Authors: Agathe Vrillon, Elsa Mhanna, Clément Aveneau, Manon Lebozec, Lina Grosset, Diane Nankam, Fernanda Albuquerque, Raphaelle Razou Feroldi, Barbara Maakaroun, Iana Pissareva, Dalenda Cherni Gherissi, Julien Azuar, Véronique François, Claire Hourrègue, Julien Dumurgier, Lisette Volpe-Gillot…

    Citation: Alzheimer's Research & Therapy 2021 13:77

    Content type: Research

    Published on:

  5. Aducanumab is an anti-amyloid-β (Aβ) antibody that achieved reduced amyloid pathology in Alzheimer’s disease (AD) trials; however, it is controversial whether it also improved cognition, which has been suggest...

    Authors: Gerhard Leinenga, Wee Kiat Koh and Jürgen Götz

    Citation: Alzheimer's Research & Therapy 2021 13:76

    Content type: Research

    Published on:

  6. We examined in cognitively intact older adults the relative weight of cognitive, genetic, structural and amyloid brain imaging variables for predicting cognitive change over a 4-year time course.

    Authors: Jolien M. Schaeverbeke, Silvy Gabel, Karen Meersmans, Emma S. Luckett, Steffi De Meyer, Katarzyna Adamczuk, Natalie Nelissen, Valerie Goovaerts, Ahmed Radwan, Stefan Sunaert, Patrick Dupont, Koen Van Laere and Rik Vandenberghe

    Citation: Alzheimer's Research & Therapy 2021 13:75

    Content type: Research

    Published on:

  7. Subjective cognitive decline (SCD) represents a cognitively normal state but at an increased risk for developing Alzheimer’s disease (AD). Recognizing the glucose metabolic biomarkers of SCD could facilitate t...

    Authors: Qiu-Yue Dong, Tao-Ran Li, Xue-Yan Jiang, Xiao-Ni Wang, Ying Han and Jie-Hui Jiang

    Citation: Alzheimer's Research & Therapy 2021 13:74

    Content type: Research

    Published on:

  8. Major depression (MD) is the most prevalent psychiatric disease in the population and is considered a prodromal stage of the Alzheimer’s disease (AD). Despite both diseases having a robust genetic component, t...

    Authors: Ana Martín-Sánchez, Janet Piñero, Lara Nonell, Magdalena Arnal, Elena M. Ribe, Alejo Nevado-Holgado, Simon Lovestone, Ferran Sanz, Laura I. Furlong and Olga Valverde

    Citation: Alzheimer's Research & Therapy 2021 13:73

    Content type: Research

    Published on:

  10. Multiple pathophysiological processes have been described in Alzheimer’s disease (AD). Their inter-individual variations, complex interrelations, and relevance for clinical manifestation and disease progressio...

    Authors: Christopher Clark, Loïc Dayon, Mojgan Masoodi, Gene L. Bowman and Julius Popp

    Citation: Alzheimer's Research & Therapy 2021 13:71

    Content type: Research

    Published on:

  11. It is currently unknown whether exergaming is efficacious in people with major neurocognitive disorder (MNCD) residing in long-term care facilities. This pilot randomized controlled trial (RCT) explored the ef...

    Authors: Nathalie Swinnen, Mathieu Vandenbulcke, Eling D. de Bruin, Riekje Akkerman, Brendon Stubbs, Joseph Firth and Davy Vancampfort

    Citation: Alzheimer's Research & Therapy 2021 13:70

    Content type: Research

    Published on:

  12. To investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer’s disease.

    Authors: Cécile Tissot, Andréa L. Benedet, Joseph Therriault, Tharick A. Pascoal, Firoza Z. Lussier, Paramita Saha-Chaudhuri, Mira Chamoun, Melissa Savard, Sulantha S. Mathotaarachchi, Gleb Bezgin, Yi-Ting Wang, Jaime Fernandez Arias, Juan Lantero Rodriguez, Anniina Snellman, Nicholas J. Ashton, Thomas K. Karikari…

    Citation: Alzheimer's Research & Therapy 2021 13:69

    Content type: Research

    Published on:

  13. Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer’s disease (AD) pathology in the form of AD-relate...

    Authors: Claudia Cicognola, Shorena Janelidze, Joakim Hertze, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2021 13:68

    Content type: Research

    Published on:

  14. A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the popul...

    Authors: Santiago Bullich, Núria Roé-Vellvé, Marta Marquié, Susan M. Landau, Henryk Barthel, Victor L. Villemagne, Ángela Sanabria, Juan Pablo Tartari, Oscar Sotolongo-Grau, Vincent Doré, Norman Koglin, Andre Müller, Audrey Perrotin, Aleksandar Jovalekic, Susan De Santi, Lluís Tárraga…

    Citation: Alzheimer's Research & Therapy 2021 13:67

    Content type: Research

    Published on:

  15. Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized that GV1001 might have beneficial effects in patients with...

    Authors: Seong-Ho Koh, Hyuk Sung Kwon, Seong Hye Choi, Jee Hyang Jeong, Hae Ri Na, Chan Nyoung Lee, YoungSoon Yang, Ae Young Lee, Jae-Hong Lee, Kyung Won Park, Hyun Jeong Han, Byeong C. Kim, Jin Se Park, Jee-Young Lee, Sangjae Kim and Kyu-Yong Lee

    Citation: Alzheimer's Research & Therapy 2021 13:66

    Content type: Research

    Published on:

  16. To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-tau181) to inform about cerebral Alzheimer’s disease (AD) pathology and predict clinical progression in a memory clin...

    Authors: Christopher Clark, Piotr Lewczuk, Johannes Kornhuber, Jonas Richiardi, Bénédicte Maréchal, Thomas K. Karikari, Kaj Blennow, Henrik Zetterberg and Julius Popp

    Citation: Alzheimer's Research & Therapy 2021 13:65

    Content type: Research

    Published on:

  17. To explore the utility of the International Working Group (IWG)-1 criteria in recruitment for Alzheimer’s disease (AD) clinical trials, we applied the more recently proposed research diagnostic criteria to ind...

    Authors: Anna Rosenberg, Alina Solomon, Hilkka Soininen, Pieter Jelle Visser, Kaj Blennow, Tobias Hartmann and Miia Kivipelto

    Citation: Alzheimer's Research & Therapy 2021 13:64

    Content type: Research

    Published on:

  18. Missing data can complicate the interpretability of a clinical trial, especially if the proportion is substantial and if there are different, potentially outcome-dependent causes.

    Authors: Floor M. van Oudenhoven, Sophie H. N. Swinkels, Hilkka Soininen, Miia Kivipelto, Tobias Hartmann and Dimitris Rizopoulos

    Citation: Alzheimer's Research & Therapy 2021 13:63

    Content type: Research

    Published on:

  19. New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide with a novel proposed mechanism of action. The first phase 3 clinical trial of G...

    Authors: Shifu Xiao, Piu Chan, Tao Wang, Zhen Hong, Shuzhen Wang, Weihong Kuang, Jincai He, Xiaoping Pan, Yuying Zhou, Yong Ji, Luning Wang, Yan Cheng, Ying Peng, Qinyong Ye, Xiaoping Wang, Yuncheng Wu…

    Citation: Alzheimer's Research & Therapy 2021 13:62

    Content type: Research

    Published on:

  20. Dementia is a progressive neurocognitive disease with a substantial social burden. No apparent breakthroughs in treatment options have emerged so far; thus, disease prevention is essential for at-risk populati...

    Authors: Yoo Jin Jang, Cinoo Kang, Woojae Myung, Shinn-Won Lim, Young Kyung Moon, Ho Kim and Doh Kwan Kim

    Citation: Alzheimer's Research & Therapy 2021 13:61

    Content type: Research

    Published on:

  21. Generative adversarial networks (GAN) can produce images of improved quality but their ability to augment image-based classification is not fully explored. We evaluated if a modified GAN can learn from magneti...

    Authors: Xiao Zhou, Shangran Qiu, Prajakta S. Joshi, Chonghua Xue, Ronald J. Killiany, Asim Z. Mian, Sang P. Chin, Rhoda Au and Vijaya B. Kolachalama

    Citation: Alzheimer's Research & Therapy 2021 13:60

    Content type: Research

    Published on:

  22. Impaired axonal transport may contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) and Down syndrome (DS). Axonal transport is a complex process in which specific mo...

    Authors: Xu-Qiao Chen, Utpal Das, Gooho Park and William C. Mobley

    Citation: Alzheimer's Research & Therapy 2021 13:59

    Content type: Research

    Published on:

  23. Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide....

    Authors: Emily B. Button, Wai Hang Cheng, Carlos Barron, Honor Cheung, Asma Bashir, Jennifer Cooper, Jasmine Gill, Sophie Stukas, David C. Baron, Jerome Robert, Elyn M. Rowe, Peter A. Cripton and Cheryl L. Wellington

    Citation: Alzheimer's Research & Therapy 2021 13:58

    Content type: Research

    Published on:

  24. Regenerative therapies to mitigate Alzheimer’s disease (AD) neuropathology have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells h...

    Authors: Lauren A. Apodaca, Al Anoud D. Baddour, Camilo Garcia Jr, Leila Alikhani, Erich Giedzinski, Ning Ru, Anshu Agrawal, Munjal M. Acharya and Janet E. Baulch

    Citation: Alzheimer's Research & Therapy 2021 13:57

    Content type: Research

    Published on:

  25. 27-Hydroxycholesterol (27-OH), the main circulating oxysterol in humans and the potential missing link between peripheral hypercholesterolemia and Alzheimer’s disease (AD), has not been investigated previously...

    Authors: Anna Sandebring-Matton, Julen Goikolea, Ingemar Björkhem, Laura Paternain, Nina Kemppainen, Tiina Laatikainen, Tiia Ngandu, Juha Rinne, Hilkka Soininen, Angel Cedazo-Minguez, Alina Solomon and Miia Kivipelto

    Citation: Alzheimer's Research & Therapy 2021 13:56

    Content type: Research

    Published on:

  26. Single-nucleotide polymorphisms (SNPs) identified by genome-wide association studies only explain part of the heritability of Alzheimer’s disease (AD). Epistasis has been considered as one of the main causes o...

    Authors: Hui Wang, David A. Bennett, Philip L. De Jager, Qing-Ye Zhang and Hong-Yu Zhang

    Citation: Alzheimer's Research & Therapy 2021 13:55

    Content type: Research

    Published on:

  27. Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer’s disease (AD) is important for the understanding of disease pathophysiology and also crucial to be ab...

    Authors: Julia Remnestål, Sofia Bergström, Jennie Olofsson, Evelina Sjöstedt, Mathias Uhlén, Kaj Blennow, Henrik Zetterberg, Anna Zettergren, Silke Kern, Ingmar Skoog, Peter Nilsson and Anna Månberg

    Citation: Alzheimer's Research & Therapy 2021 13:54

    Content type: Research

    Published on:

  28. The DEmEntia with LEwy bOdies Project (DEvELOP) aims to phenotype patients with dementia with Lewy bodies (DLB) and study the symptoms and biomarkers over time. Here, we describe the design and baseline result...

    Authors: M. van de Beek, I. van Steenoven, J. J. van der Zande, I. Porcelijn, F. Barkhof, C. J. Stam, P. G. H. M. Raijmakers, P. Scheltens, C. E. Teunissen, W. M. van der Flier and A. W. Lemstra

    Citation: Alzheimer's Research & Therapy 2021 13:53

    Content type: Research

    Published on:

  30. Brain energy metabolism is impaired in Alzheimer’s disease (AD), which may be mitigated by a ketogenic diet. We conducted a randomized crossover trial to determine whether a 12-week modified ketogenic diet imp...

    Authors: Matthew C. L. Phillips, Laura M. Deprez, Grace M. N. Mortimer, Deborah K. J. Murtagh, Stacey McCoy, Ruth Mylchreest, Linda J. Gilbertson, Karen M. Clark, Patricia V. Simpson, Eileen J. McManus, Jee-Eun Oh, Satish Yadavaraj, Vanessa M. King, Avinesh Pillai, Beatriz Romero-Ferrando, Martijn Brinkhuis…

    Citation: Alzheimer's Research & Therapy 2021 13:51

    Content type: Research

    Published on:

  31. Dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) are recognised to be under-recognised in clinical practice in the UK, with only one third to a half of expected cases diagnosed. We aim...

    Authors: A. Surendranathan, J. Kane, A. Bentley, S. Barker, R. McNally, C. Bamford, J.-P. Taylor, A. Thomas, I. McKeith, D. Burn and J. T. O’Brien

    Citation: Alzheimer's Research & Therapy 2021 13:50

    Content type: Research

    Published on:

  32. Previous research has described distinct subtypes of Alzheimer’s disease (AD) based on the differences in regional patterns of brain atrophy on MRI. We conducted a data-driven exploration of distinct AD neurod...

    Authors: Fedor Levin, Daniel Ferreira, Catharina Lange, Martin Dyrba, Eric Westman, Ralph Buchert, Stefan J. Teipel and Michel J. Grothe

    Citation: Alzheimer's Research & Therapy 2021 13:49

    Content type: Research

    Published on:

  33. The presence of ß-amyloid (Aß) in the brain can be identified using amyloid PET. In clinical practice, the amyloid PET is interpreted based on dichotomous visual rating, which renders focal Aß accumulation be ...

    Authors: Si Eun Kim, Byungju Lee, Hyemin Jang, Juhee Chin, Ching Soong Khoo, Yeong Sim Choe, Ji Sun Kim, Sung Hoon Kang, Hang-Rai Kim, Song Hwangbo, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Jae-Won Jang…

    Citation: Alzheimer's Research & Therapy 2021 13:48

    Content type: Research

    Published on:

  34. Type 2 diabetes is a risk factor for Alzheimer’s disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is stil...

    Authors: Grazia Daniela Femminella, Nicholas R. Livingston, Sanara Raza, Thalia van der Doef, Eleni Frangou, Sharon Love, Gail Busza, Valeria Calsolaro, Stefan Carver, Clive Holmes, Craig W. Ritchie, Robert M. Lawrence, Brady McFarlane, George Tadros, Basil H. Ridha, Carol Bannister…

    Citation: Alzheimer's Research & Therapy 2021 13:47

    Content type: Research

    Published on:

  35. Recognizing clinical manifestations heralding the development of Alzheimer’s disease (AD)-related cognitive impairment could improve the identification of individuals at higher risk of AD who may benefit from ...

    Authors: Oriol Grau-Rivera, Irene Navalpotro-Gomez, Gonzalo Sánchez-Benavides, Marc Suárez-Calvet, Marta Milà-Alomà, Eider M. Arenaza-Urquijo, Gemma Salvadó, Aleix Sala-Vila, Mahnaz Shekari, José Maria González-de-Echávarri, Carolina Minguillón, Aida Niñerola-Baizán, Andrés Perissinotti, Maryline Simon, Gwendlyn Kollmorgen, Henrik Zetterberg…

    Citation: Alzheimer's Research & Therapy 2021 13:46

    Content type: Research

    Published on:

  36. Dysregulation of ceramide and sphingomyelin levels have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers which are crucial ...

    Authors: Simone M. Crivelli, Qian Luo, Jo A.A. Stevens, Caterina Giovagnoni, Daan van Kruining, Gerard Bode, Sandra den Hoedt, Barbara Hobo, Anna-Lena Scheithauer, Jochen Walter, Monique T. Mulder, Christopher Exley, Matthew Mold, Michelle M. Mielke, Helga E. De Vries, Kristiaan Wouters…

    Citation: Alzheimer's Research & Therapy 2021 13:45

    Content type: Research

    Published on:

  37. In recent years, excellent results have suggested an association between the “brain-gut” axis and Alzheimer’s disease (AD) progression, yet the role of the “brain-gut” axis in AD pathogenesis still remains obs...

    Authors: Xinru Gu, Junyi Zhou, Yanyan Zhou, Hongjie Wang, Nan Si, Wei Ren, Wei Zhao, Xiaorui Fan, Wenya Gao, Xiaolu Wei, Jian Yang, Baolin Bian and Haiyu Zhao

    Citation: Alzheimer's Research & Therapy 2021 13:44

    Content type: Research

    Published on:

  38. The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action, but prior work suggests divergence in their ef...

    Authors: Michael Ouk, Che-Yuan Wu, Jennifer S. Rabin, Aaron Jackson, Jodi D. Edwards, Joel Ramirez, Mario Masellis, Richard H. Swartz, Nathan Herrmann, Krista L. Lanctôt, Sandra E. Black and Walter Swardfager

    Citation: Alzheimer's Research & Therapy 2021 13:43

    Content type: Research

    Published on:

  39. PET imaging of glucose metabolism has revealed presymptomatic abnormalities in genetic FTD but has not been explored in MAPT P301L mutation carriers. This study aimed to explore the patterns of presymptomatic hyp...

    Authors: Mica T. M. Clarke, Frédéric St-Onge, Jean-Mathieu Beauregard, Martina Bocchetta, Emily Todd, David M. Cash, Jonathan D. Rohrer and Robert Laforce Jr

    Citation: Alzheimer's Research & Therapy 2021 13:42

    Content type: Research

    Published on:

  40. Observational studies suggest that the use of antihypertensive medications (AHMs) is associated with a reduced risk of Alzheimer’s disease (AD); however, these findings may be biased by confounding and reverse...

    Authors: Ya-Nan Ou, Yu-Xiang Yang, Xue-Ning Shen, Ya-Hui Ma, Shi-Dong Chen, Qiang Dong, Lan Tan and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2021 13:41

    Content type: Research

    Published on:

  41. The neuropathological hallmarks of Alzheimer’s disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). The amyloid cascade theory is the leading hypothesis of AD pathology. Aβ deposition pr...

    Authors: Yanxing Chen, Shuai Zhao, Ziqi Fan, Zheyu Li, Yueli Zhu, Ting Shen, Kaicheng Li, Yaping Yan, Jun Tian, Zhirong Liu and Baorong Zhang

    Citation: Alzheimer's Research & Therapy 2021 13:40

    Content type: Research

    Published on:

  42. Current tasks measuring social cognition are usually ‘pen and paper’ tasks, have ceiling effects and include complicated test instructions that may be difficult to understand for those with cognitive impairmen...

    Authors: Lucy L. Russell, Caroline V. Greaves, Rhian S. Convery, Jennifer Nicholas, Jason D. Warren, Diego Kaski and Jonathan D. Rohrer

    Citation: Alzheimer's Research & Therapy 2021 13:39

    Content type: Research

    Published on:

  43. Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mi...

    Authors: Claudia Cicognola, Oskar Hansson, Philip Scheltens, Hlin Kvartsberg, Henrik Zetterberg, Charlotte E. Teunissen and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2021 13:38

    Content type: Research

    Published on:

  44. Synaptic failure is one of the principal events associated with cognitive dysfunction in Alzheimer’s disease (AD). Preservation of existing synapses and prevention of synaptic loss are promising strategies to ...

    Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar

    Citation: Alzheimer's Research & Therapy 2021 13:37

    Content type: Research

    Published on:

  45. β-amyloid (Aβ) and tau positron emission tomography (PET) detect the pathological changes that define Alzheimer’s disease (AD) in living people. Cognitive measures sensitive to Aβ and tau burden may help strea...

    Authors: Elena Tsoy, Amelia Strom, Leonardo Iaccarino, Sabrina J. Erlhoff, Collette A. Goode, Anne-Marie Rodriguez, Gil D. Rabinovici, Bruce L. Miller, Joel H. Kramer, Katherine P. Rankin, Renaud La Joie and Katherine L. Possin

    Citation: Alzheimer's Research & Therapy 2021 13:36

    Content type: Research

    Published on:

  46. The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study, ...

    Authors: Emma M. Coomans, Deborah N. Schoonhoven, Hayel Tuncel, Sander C. J. Verfaillie, Emma E. Wolters, Ronald Boellaard, Rik Ossenkoppele, Anouk den Braber, Wiep Scheper, Patrick Schober, Steven P. Sweeney, J. Michael Ryan, Robert C. Schuit, Albert D. Windhorst, Frederik Barkhof, Philip Scheltens…

    Citation: Alzheimer's Research & Therapy 2021 13:35

    Content type: Research

    Published on:

  47. Identification of genetic risk factors that are shared between Alzheimer’s disease (AD) and other traits, i.e., pleiotropy, can help improve our understanding of the etiology of AD and potentially detect new t...

    Authors: William P. Bone, Katherine M. Siewert, Anupama Jha, Derek Klarin, Scott M. Damrauer, Kyong-Mi Chang, Philip S. Tsao, Themistocles L. Assimes, Marylyn D. Ritchie and Benjamin F. Voight

    Citation: Alzheimer's Research & Therapy 2021 13:34

    Content type: Research

    Published on:

  48. Physical inactivity has been consistently linked to increased risk of cognitive decline; however, studies examining the impact of exercise interventions on cognition have produced inconsistent findings. Some o...

    Authors: Belinda M. Brown, Natalie Frost, Stephanie R. Rainey-Smith, James Doecke, Shaun Markovic, Nicole Gordon, Michael Weinborn, Hamid R. Sohrabi, Simon M. Laws, Ralph N. Martins, Kirk I. Erickson and Jeremiah J. Peiffer

    Citation: Alzheimer's Research & Therapy 2021 13:33

    Content type: Research

    Published on:

  49. Prominent activation of microglial immune/inflammatory processes is a characteristic feature of brains of patients with tauopathies including Alzheimer’s disease (AD), suggesting that neuroinflammation may be ...

    Authors: Yun-Beom Choi, Ambrose A. Dunn-Meynell, Michelle Marchese, Benjamin M. Blumberg, Deeya Gaindh, Peter C. Dowling and Wei Lu

    Citation: Alzheimer's Research & Therapy 2021 13:32

    Content type: Research

    Published on:

  50. APOE ε4 carrier status is known to increase odds of amnestic presentations with Alzheimer’s pathology. It is unknown how APOE ε4 carrier status impacts odds of specific initial cognitive symptoms in the presence ...

    Authors: Jagan A. Pillai, James Bena, Aaron Bonner-Jackson and James B. Leverenz

    Citation: Alzheimer's Research & Therapy 2021 13:31

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193